Developer docs
API playgroundTry for free, no card

Search company profiles

Circe Biomedical

Full company profile

uuid003ga6w

Namestring
Circe Biomedical
Legal namestring
Circe Biomedical, Inc.
Websiteurl
circebio.com
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Circe Biomedical is a privately held, development-stage biotechnology company founded in 1999 and headquartered at 99 Hayden Avenue in Lexington, Massachusetts. The company is engaged in the development, production, and intended commercialization of bioartificial organs and therapeutic cell systems designed to replace the function of failing liver and pancreatic organs by integrating living cells with extracorporeal and implantable devices. Its intended end users are patients with acute liver failure (bridged to organ recovery or transplantation) and insulin-dependent diabetics.

The company's product portfolio rests on two proprietary technology pillars: isolation, purification, and cryopreservation of primary mammalian cells, and fabrication of semipermeable biocompatible membranes that regulate molecular passage and provide immunologic isolation. Its lead program, the HepatAssist Liver Support System, is an extracorporeal bioartificial liver device incorporating primary pig hepatocytes in a hollow fiber bioreactor with charcoal columns, a membrane oxygenator, and a pump; each treatment session runs six hours, with cryopreserved cells shipped to clinical sites. Circe states the HepatAssist system has advanced further in controlled clinical trials for acute liver failure than any competing system. Its second program, the PancreAssist System, is an implantable, disk-shaped bioartificial pancreas enclosing pancreatic islets within a tubular membrane; it is in preclinical development and is designed to deliver physiologic insulin response without immunosuppressant drugs. Both HepatAssist and PancreAssist are registered trademarks.

Circe has not yet commercialized a product and is pre-revenue. Its anticipated revenue model, once approved, is hardware and consumable sales of medical devices and disposable cell-based cartridges to hospital transplant centers and acute care facilities, distributed through direct clinical partnerships. The company raised $28 million in a December 2000 financing led by Polaris Partners, with Advanced Technology Ventures, Burrill & Company, and HLM Management Company participating. The leadership team is led by President and CEO Elizabeth Chen, CFO Ted Owens, and VP Operations Shawn Cain, with a small group of directors covering clinical operations, quality systems, and regulatory affairs. The company website carries a 2002 copyright and the contact page states the firm is not contracting new services or supplementing staffing, indicating a very small, maintenance-mode operation as of the most recent publicly available signals.

Short descriptiontext

Circe Biomedical is a privately held, development-stage biotechnology company developing bioartificial organ systems — the HepatAssist extracorporeal liver support device (in clinical trials) and the PancreAssist implantable bioartificial pancreas (in preclinical development) — for patients with acute liver failure and insulin-dependent diabetes.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLexington, United States
HQ citystring
Lexington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bioartificial organ systems, liver support devices, cell therapy technology, biocompatible membrane devices, implantable pancreas systems
Industry2 codes
PRIMARYHLAKAEAB
Hepatology & Liver Disease
SECONDARYHLAKAEAK
Transplant Hepatology
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Bioartificial Medical Devices
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Bioartificial Organ Systems Commercialization
TypeHardware Sales
Description

Development-stage company focused on commercializing bioartificial organs and therapeutic cell systems. Revenue model anticipated to be through sale of medical devices and related consumables for liver and pancreatic support systems.

circebio.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1HepatAssist
Description

HepatAssist® Liver Support System - an extracorporeal, bioartificial liver support system incorporating primary hepatocytes (pig liver cells) designed to treat patients with acute liver failure.

circebio.com
+1 more record
Core offering1 text field

Circe Biomedical develops and intends to commercialize bioartificial organ systems for liver and pancreatic diseases. Its lead product, the HepatAssist Liver Support System, is an extracorporeal bioartificial liver incorporating primary pig hepatocytes in a hollow fiber bioreactor to bridge acute liver failure patients to recovery or transplantation. The preclinical PancreAssist System is an implantable bioartificial pancreas that uses a proprietary semipermeable membrane to provide immunologic isolation of pancreatic islets for insulin-dependent diabetes therapy.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Circe Biomedical is developing bioartificial organ systems based on proprietary mammalian cell and semi-permeable membrane technologies. The company's portfolio consists of two distinct products: the HepatAssist® Liver Support System, an extracorporeal device currently in clinical development for acute liver failure that integrates primary hepatocytes with biocompatible membranes; and the PancreAssist® System, an implantable bioartificial pancreas in preclinical development for insulin-dependent diabetes that incorporates pancreatic islets within a membrane-based housing. Both systems leverage the company's core technology platform combining isolated mammalian cells with semipermeable membranes to replace organ function.

Product and service2 records
1HepatAssist Liver Support System
CategoryBioartificial Medical Device
Description

An extracorporeal bioartificial liver support system incorporating primary hepatocytes (pig liver cells) in a hollow fiber bioreactor, with charcoal columns, a membrane oxygenator, and a pump. Each treatment lasts 6 hours, with cryopreserved hepatocytes shipped to clinical sites and thawed prior to treatment. It is intended for patients with acute liver failure who need temporary liver function support to bridge them to organ recovery or transplantation, used in hospital transplant centers and acute care facilities.

2PancreAssist System
CategoryBioartificial Medical Device
Description

An implantable bioartificial pancreas incorporating living pancreatic islets within a single tubular semipermeable membrane enclosed in a disk-shaped housing, designed for implantation near the kidney and connection to the circulatory system via standard vascular grafts. The membrane pores prevent white blood cells and antibodies from attacking the islets, eliminating the need for immunosuppressant drugs, and the device is intended to provide insulin in response to blood glucose changes for patients with insulin-dependent diabetes.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1ViaCyte
TypeDirect peer
Description

Develops encapsulated stem-cell-derived pancreatic progenitor therapies for insulin-dependent diabetes using immunoprotective membranes — the closest functional analog to Circe's PancreAssist, with a similar mission of immunosuppression-free cell replacement.

TypeBroad incumbent
Description

Publicly traded commercial-stage regenerative medicine company using living cell-based products. Relevant as a broader incumbent in cell-based therapeutics, though its product focus (wound care) is adjacent to Circe's organ-replacement focus.

3Aspect Biosystems
TypeEmerging player
Description

Developer of 3D bioprinted tissue therapeutics, including pancreatic tissue for diabetes. Relevant as an emerging player pursuing cell-based organ replacement with an alternative (bioprinting) manufacturing approach.

TypeBroad incumbent
Description

Large-cap biopharmaceutical company that acquired Semma Therapeutics and is advancing the leading stem-cell-derived therapy for type 1 diabetes (zimislecel). Represents the most capitalized competitive threat to PancreAssist in insulin-dependent diabetes.

5Teraklin (now part of CytoPherx / HepaWash)
TypeDirect peer
Description

Developer of extracorporeal liver support therapies (MARS-like cell-free systems and successor approaches). A direct competitor in the acute liver failure supportive care market where HepatAssist would compete.

TypeDirect peer
Description

French developer of MailPan, an implantable bioartificial pancreas using semipermeable membranes to encapsulate pancreatic islets. Shares Circe's core thesis of immunoisolated cell therapy for diabetes without immunosuppression.

7Vital Therapies
TypeDirect peer
Description

Developer of the ELAD (Extracorporeal Liver Assist Device) bioartificial liver system, the most direct head-to-head competitor to Circe's HepatAssist in the acute liver failure space. Both companies pursued extracorporeal cell-based liver support as a bridge to transplant or recovery.

TypeDirect peer
Description

Developed stem-cell-derived islet cell therapies for type 1 diabetes (acquired by Vertex Pharmaceuticals). Directly comparable to PancreAssist in its goal of restoring insulin production in insulin-dependent diabetics, though using a different encapsulation/cell approach.

9Arbios Systems
TypeDirect peer
Description

Developed the SEPET bioartificial liver system, another extracorporeal cell-based liver support device. Directly comparable to Circe in technology approach and target indication (acute liver failure).

TypeDirect peer
Description

Developer of the BLSS (Bioartificial Liver Support System), another extracorporeal bioartificial liver device. Directly comparable to HepatAssist in modality, indication, and target clinical sites (transplant centers).

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Circe Biomedical

Bioartificial Medical Devicescircebio.com

Circe Biomedical is a privately held, development-stage biotechnology company developing bioartificial organ systems — the HepatAssist extracorporeal liver support device (in clinical trials) and the PancreAssist implantable bioartificial pancreas (in preclinical development) — for patients with acute liver failure and insulin-dependent diabetes.

What Circe Biomedical does

Circe Biomedical is a privately held, development-stage biotechnology company founded in 1999 and headquartered at 99 Hayden Avenue in Lexington, Massachusetts. The company is engaged in the development, production, and intended commercialization of bioartificial organs and therapeutic cell systems designed to replace the function of failing liver and pancreatic organs by integrating living cells with extracorporeal and implantable devices. Its intended end users are patients with acute liver failure (bridged to organ recovery or transplantation) and insulin-dependent diabetics.

The company's product portfolio rests on two proprietary technology pillars: isolation, purification, and cryopreservation of primary mammalian cells, and fabrication of semipermeable biocompatible membranes that regulate molecular passage and provide immunologic isolation. Its lead program, the HepatAssist Liver Support System, is an extracorporeal bioartificial liver device incorporating primary pig hepatocytes in a hollow fiber bioreactor with charcoal columns, a membrane oxygenator, and a pump; each treatment session runs six hours, with cryopreserved cells shipped to clinical sites. Circe states the HepatAssist system has advanced further in controlled clinical trials for acute liver failure than any competing system. Its second program, the PancreAssist System, is an implantable, disk-shaped bioartificial pancreas enclosing pancreatic islets within a tubular membrane; it is in preclinical development and is designed to deliver physiologic insulin response without immunosuppressant drugs. Both HepatAssist and PancreAssist are registered trademarks.

Circe has not yet commercialized a product and is pre-revenue. Its anticipated revenue model, once approved, is hardware and consumable sales of medical devices and disposable cell-based cartridges to hospital transplant centers and acute care facilities, distributed through direct clinical partnerships. The company raised $28 million in a December 2000 financing led by Polaris Partners, with Advanced Technology Ventures, Burrill & Company, and HLM Management Company participating. The leadership team is led by President and CEO Elizabeth Chen, CFO Ted Owens, and VP Operations Shawn Cain, with a small group of directors covering clinical operations, quality systems, and regulatory affairs. The company website carries a 2002 copyright and the contact page states the firm is not contracting new services or supplementing staffing, indicating a very small, maintenance-mode operation as of the most recent publicly available signals.

Circe Biomedical firmographics

Firmographics
Name
Circe Biomedical
Legal name
Circe Biomedical, Inc.
Website
https://circebio.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
11–50 employees
Short description
Circe Biomedical is a privately held, development-stage biotechnology company developing bioartificial organ systems — the HepatAssist extracorporeal liver support device (in clinical trials) and the PancreAssist implantable bioartificial pancreas (in preclinical development) — for patients with acute liver failure and insulin-dependent diabetes.
Ownership category
akta.pro rank

Circe Biomedical industry classification

Industry
Product category
Bioartificial Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAKAEAB
Hepatology & Liver Disease
SECONDARYHLAKAEAK
Transplant Hepatology

Keywords

  • Bioartificial organ systems
  • Liver support devices
  • Cell therapy technology
  • Biocompatible membrane devices
  • Implantable pancreas systems

Where Circe Biomedical is headquartered

Location

Headquarters

HQ city
Lexington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Circe Biomedical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Bioartificial Organ Systems Commercialization: Development-stage company focused on commercializing bioartificial organs and therapeutic cell systems. Revenue model anticipated to be through sale of medical devices and related consumables for liver and pancreatic support systems.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Circe Biomedical product offering

Product offering

Core offering

Circe Biomedical develops and intends to commercialize bioartificial organ systems for liver and pancreatic diseases. Its lead product, the HepatAssist Liver Support System, is an extracorporeal bioartificial liver incorporating primary pig hepatocytes in a hollow fiber bioreactor to bridge acute liver failure patients to recovery or transplantation. The preclinical PancreAssist System is an implantable bioartificial pancreas that uses a proprietary semipermeable membrane to provide immunologic isolation of pancreatic islets for insulin-dependent diabetes therapy.

Product overview

Circe Biomedical is developing bioartificial organ systems based on proprietary mammalian cell and semi-permeable membrane technologies. The company's portfolio consists of two distinct products: the HepatAssist® Liver Support System, an extracorporeal device currently in clinical development for acute liver failure that integrates primary hepatocytes with biocompatible membranes; and the PancreAssist® System, an implantable bioartificial pancreas in preclinical development for insulin-dependent diabetes that incorporates pancreatic islets within a membrane-based housing. Both systems leverage the company's core technology platform combining isolated mammalian cells with semipermeable membranes to replace organ function.

Differentiator

Problem solved

Functional benefit

Brands

  • HepatAssist: HepatAssist® Liver Support System - an extracorporeal, bioartificial liver support system incorporating primary hepatocytes (pig liver cells) designed to treat patients with acute liver failure.
  • PancreAssist

Products and services

  • HepatAssist Liver Support System An extracorporeal bioartificial liver support system incorporating primary hepatocytes (pig liver cells) in a hollow fiber bioreactor, with charcoal columns, a membrane oxygenator, and a pump. Each treatment lasts 6 hours, with cryopreserved hepatocytes shipped to clinical sites and thawed prior to treatment. It is intended for patients with acute liver failure who need temporary liver function support to bridge them to organ recovery or transplantation, used in hospital transplant centers and acute care facilities.
  • PancreAssist System An implantable bioartificial pancreas incorporating living pancreatic islets within a single tubular semipermeable membrane enclosed in a disk-shaped housing, designed for implantation near the kidney and connection to the circulatory system via standard vascular grafts. The membrane pores prevent white blood cells and antibodies from attacking the islets, eliminating the need for immunosuppressant drugs, and the device is intended to provide insulin in response to blood glucose changes for patients with insulin-dependent diabetes.

Companies that use Circe Biomedical

Customer profile

Segments2 records

Ideal customer profiles2 records

Circe Biomedical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Circe Biomedical partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Circe Biomedical competitors and assessment

Company assessment

Direct peers

  • ViaCyte: Develops encapsulated stem-cell-derived pancreatic progenitor therapies for insulin-dependent diabetes using immunoprotective membranes — the closest functional analog to Circe's PancreAssist, with a similar mission of immunosuppression-free cell replacement.
  • Teraklin (now part of CytoPherx / HepaWash): Developer of extracorporeal liver support therapies (MARS-like cell-free systems and successor approaches). A direct competitor in the acute liver failure supportive care market where HepatAssist would compete.
  • Defymed: French developer of MailPan, an implantable bioartificial pancreas using semipermeable membranes to encapsulate pancreatic islets. Shares Circe's core thesis of immunoisolated cell therapy for diabetes without immunosuppression.
  • Vital Therapies: Developer of the ELAD (Extracorporeal Liver Assist Device) bioartificial liver system, the most direct head-to-head competitor to Circe's HepatAssist in the acute liver failure space. Both companies pursued extracorporeal cell-based liver support as a bridge to transplant or recovery.
  • Semma Therapeutics (Vertex Cell Therapy): Developed stem-cell-derived islet cell therapies for type 1 diabetes (acquired by Vertex Pharmaceuticals). Directly comparable to PancreAssist in its goal of restoring insulin production in insulin-dependent diabetics, though using a different encapsulation/cell approach.
  • Arbios Systems: Developed the SEPET bioartificial liver system, another extracorporeal cell-based liver support device. Directly comparable to Circe in technology approach and target indication (acute liver failure).
  • Excorp Medical: Developer of the BLSS (Bioartificial Liver Support System), another extracorporeal bioartificial liver device. Directly comparable to HepatAssist in modality, indication, and target clinical sites (transplant centers).

Broad incumbents

  • Organogenesis: Publicly traded commercial-stage regenerative medicine company using living cell-based products. Relevant as a broader incumbent in cell-based therapeutics, though its product focus (wound care) is adjacent to Circe's organ-replacement focus.
  • Vertex Pharmaceuticals: Large-cap biopharmaceutical company that acquired Semma Therapeutics and is advancing the leading stem-cell-derived therapy for type 1 diabetes (zimislecel). Represents the most capitalized competitive threat to PancreAssist in insulin-dependent diabetes.

Emerging players

  • Aspect Biosystems: Developer of 3D bioprinted tissue therapeutics, including pancreatic tissue for diabetes. Relevant as an emerging player pursuing cell-based organ replacement with an alternative (bioprinting) manufacturing approach.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Circe Biomedical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Circe Biomedical leadership team

Management profile

Number of profiles

Profiles6 records

Circe Biomedical funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Circe Biomedical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Circe Biomedical

What does Circe Biomedical do?

Circe Biomedical develops and intends to commercialize bioartificial organ systems for liver and pancreatic diseases. Its lead product, the HepatAssist Liver Support System, is an extracorporeal bioartificial liver incorporating primary pig hepatocytes in a hollow fiber bioreactor to bridge acute liver failure patients to recovery or transplantation. The preclinical PancreAssist System is an implantable bioartificial pancreas that uses a proprietary semipermeable membrane to provide immunologic isolation of pancreatic islets for insulin-dependent diabetes therapy.

Is Circe Biomedical a public or private company?

Circe Biomedical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Circe Biomedical founded?

Circe Biomedical was founded in 1999. It employs 11 to 50 people.

Where is Circe Biomedical based?

Circe Biomedical is headquartered in Lexington, United States, in the North America region.

How does Circe Biomedical make money?

One revenue line is on record: bioartificial Organ Systems Commercialization.

Who are Circe Biomedical's main competitors?

Direct peers on record are ViaCyte, Teraklin (now part of CytoPherx / HepaWash), Defymed, Vital Therapies, Semma Therapeutics (Vertex Cell Therapy), Arbios Systems and Excorp Medical. Broad incumbents are Organogenesis and Vertex Pharmaceuticals. Aspect Biosystems is listed as an emerging player.

Does Circe Biomedical have an API?

No public API is recorded for Circe Biomedical.

What industry is Circe Biomedical in?

Circe Biomedical's product category is Bioartificial Medical Devices. Its primary akta.pro industry code is HLAKAEAB, Hepatology & Liver Disease, with a secondary code of HLAKAEAK, Transplant Hepatology. Its NAICS code is 339113 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales